Hebert, LE, Weuve, J, Scherr, PA, Evans, DA. Alzheimer’s disease in the USA (2010–2050) estimated using the 2010 Census. Neurology 2013;80(19):1778–83.Google Scholar

Alzheimer’s Association. 2013 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia 2013;9(2):208–45.CrossRefGoogle ScholarPubMed

Mesulam, M, Shaw, P, Mash, D, Weintraub, S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 2004;55(6):815–28.CrossRefGoogle ScholarPubMed

Whitehouse, PJ, Price, DL, Clark, AW, Coyle, JT, DeLong, MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122–6.CrossRefGoogle ScholarPubMed

Villarroya, M, García, AG, Marco, JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer’s disease. Curr Pharm Des 2004;10(25):3177–84.Google Scholar

Birks, J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006 (1): CD005593.Google ScholarPubMed

Hansen, RA, Gartlehner, G, Webb, AP, Morgan, LC, Moore, CG, Jonas, DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clin Interv Aging 2008;3(2):211–25.Google Scholar

Zhu, CW, Livote, EE, Scarmeas, N, Albert, M, Brandt, J, Blacker, D, Sano, M, Stern, Y. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer’s disease. Alzheimers Dement 2013 Jan 16; pii: S1552–5260(12)02526–5.Google ScholarPubMed

Alva, G, Cummings, JL. Relative tolerability of Alzheimer’s disease treatments. Psychiatry (Edgmont) 2008;5(11):27–36.Google Scholar

Emre, M. Switching cholinesterase inhibitors in patients with Alzheimer’s disease. Int J Clin Pract Suppl 2002 Jun;(127):64–72.CrossRefGoogle ScholarPubMed

Bartorelli, L, Giraldi, C, Saccardo, M, Cammarata, S, Bottini, G, Fasanaro, AM, Trequattrini, A. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer’s disease. Curr Med Res Opin 2005;21(11):1809–18.CrossRefGoogle ScholarPubMed

Rogawski, MA, Wenk, GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev 2003 Fall;9(3): 275–308.CrossRefGoogle ScholarPubMed

Lipton, SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders. J Alzheimers Dis 2004 Dec;6(6 Suppl):S61–74.CrossRefGoogle Scholar

McShane, R, Areosa Sastre, A, Minakaran, N. Memantine for dementia. Cochrane Database Syst Rev 2006 Apr 19;(2):CD003154.CrossRefGoogle ScholarPubMed

Maidment, ID, Fox, CG, Boustani, M, Rodriguez, J, Brown, RC, Katona, CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 2008 Jan;42(1):32–8.CrossRefGoogle Scholar

Tariot, PN, Farlow, MR, Grossberg, GT, Graham, SM, McDonald, S, Gergel, I. Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317–324.CrossRefGoogle ScholarPubMed

Feldman, HH, Schmitt, FA, Olin, JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006 Oct–Dec;20(4):263–8.CrossRefGoogle Scholar

Porsteinsson, AP, Grossberg, GT, Mintzer, J, Olin, JT. Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83–9.CrossRefGoogle ScholarPubMed

Atri, A, Molinuevo, JL, Lemming, O, Wirth, Y, Pulte, I, Wilkinson, D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 2013 Jan 21;5(1):6.CrossRefGoogle ScholarPubMed

Minoshima, S, Giordani, B, Berent, S, Frey, KA, Foster, NL, Kuhl, DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997 Jul;42(1):85–94.CrossRefGoogle ScholarPubMed

Henderson, ST. Ketone bodies as a therapeutic for Alzheimer’s disease. Neurotherapeutics 2008 Jul;5(3):470–80.CrossRefGoogle ScholarPubMed

Henderson, ST, Vogel, JL, Barr, LJ, Garvin, F, Jones, JJ, Costantini, LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009; 6:31.CrossRefGoogle ScholarPubMed

Seshadri, S, Beiser, A, Selhub, J, Jacques, PF, Rosenberg, IH, D’Agostino, RB, Wilson, PW, Wolf, PA. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002;346(7):476–83.Google Scholar

Kruman, II, Kumartavel, TS, Lohani, A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer’s disease. J Neurosci 2002;70:694–702.CrossRefGoogle ScholarPubMed

Zhang, CE, Wei, W, Liu, YH, et al. Hyperhomocysteinemia increases β-amyloid by enhancing expression of γ-secretase on phosphorylation of amyloid precursor protein in rat brain. Am J Pathol 2009;174:1481–91.CrossRefGoogle ScholarPubMed

Guidi, I, Galimberti, D, Lonarti, S, et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 2006;27(2):262–9.CrossRefGoogle ScholarPubMed

Puertas, MC, Martínez-Martos, JM, Cobo, MP, Carrera, MP, Mayas, MD, Ramírez-Expósito, MJ. Plasma oxidative stress parameters in men and women with early stage Alzheimer-type dementia. Exp Gerontol 2012;47: 625–30.CrossRefGoogle ScholarPubMed

McCaddon, A, Hudson, PR. l-methylfolate, methylcobalamin, and N-acetylcysteine in the treatment of Alzheimer’s disease-related cognitive decline. CNS Spectr 2010;15 (Suppl 1):2–5.CrossRefGoogle ScholarPubMed

de Jager, CA, Oulhaj, A, Jacoby, R, Refsum, H, Smith, AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 2012 Jun;27(6):592–600.CrossRefGoogle ScholarPubMed

Douaud, G, Refsum, H, de Jager, CA, et al. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci USA 2013 Jun 4;110(23):9523–8.CrossRefGoogle ScholarPubMed

Selkoe, DJ. Alzheimer’s disease is a synaptic failure. Science 2002;298(5594): 789–91.CrossRefGoogle Scholar

Cansev, M, Wurtman, RJ. Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils. Neuroscience 2007 Aug 24;148(2):421–31.CrossRefGoogle ScholarPubMed

Sakamoto, T, Cansev, M, Wurtman, RJ. Oral supplementation with docosahexaenoic acid and uridine-5’-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 2007 Nov 28;1182:50–9.CrossRefGoogle ScholarPubMed

Scheltens, P, Kamphuis, PJ, Verhey, FR, et al. Efficacy of a medical food in mild Alzheimer’s disease: a randomized controlled trial. Alzheimers Dement 2010; 6(1):1–10.Google ScholarPubMed

Scheltens, P, Stam, CJ, Swinkels, SH, et al. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. Journal of Alzheimer’s Disease 2012;31(1):225–36.Google Scholar

Phrma. Medicines in development: Alzheimer’s diseases. PhRMA’s Communications & Public Affairs Department. 2012. (Epub.)CrossRefGoogle ScholarPubMed

Corbett, A, Smith, J, Ballard, C. New and emerging treatments for Alzheimer’s disease. Expert Rev Neurother 2012;12(5):535–43.CrossRefGoogle ScholarPubMed

Caraci, F, Bosco, P, Leggio, GM, Malaguarnera, M, Drago, F, Bucolo, C, Salomone, S. Clinical pharmacology of novel anti-Alzheimer disease modifying medications. Curr Top Med Chem 2013;13(15):1853–63.CrossRefGoogle ScholarPubMed

Wang, Y, Mandelkow, E. Tau in physiology and pathology. Nat Rev Neurosci 2016 Jan;17(1):22–35.CrossRefGoogle ScholarPubMed

Thomsen, MS, Hansen, HH, Timmerman, DB, Mikkelsen, JD. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 2010;16(3):323–43.CrossRefGoogle Scholar

Geldenhuys, WJ, Van der Schyf, CJ. The seratonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer’s disease. Expert Rev Neurother 2009;9(7):1073–85.CrossRefGoogle ScholarPubMed

Naddafi, F, Mirshafiey, A. The neglected role of histamine in Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2013;28(4):327–36.CrossRefGoogle ScholarPubMed

Dai, Y, Kamal, MA. Fighting Alzheimer’s disease and type 2 diabetes: pathological links and treatment strategies. CNS Neurol Disord Drug Targets 2014 Mar;13(2):271–82.CrossRefGoogle ScholarPubMed

Morgan, D. Immunotherapy for Alzheimer’s disease. J Alzheimers Dis. 2006;9(3 Suppl):425–32.Google ScholarPubMed

Lambracht-Washington, D, Rosenberg, RN. Advances in the development of vaccines for Alzheimer’s disease. Discov Med 2013;15(84):319–26.CrossRefGoogle ScholarPubMed

Götz, J, Ittner, A, Ittner, LM. Tau-targeted treatment strategies in Alzheimer’s disease. Br J Pharmacol 2012;165(5):1246–59.CrossRefGoogle ScholarPubMed

Jayasena, T, Poljak, A, Smythe, G, Braidy, N, Münch, G, Sachdev, P. The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer’s disease. Ageing Res Rev 2013;12(4):867–83.CrossRefGoogle ScholarPubMed

Fang, L, Gou, S, Fang, X, Cheng, L, Fleck, C. Current progresses of novel natural products and their derivatives/analogs as anti-Alzheimer candidates: an update. Mini Rev Med Chem. 2013;13(6):870–87.CrossRefGoogle ScholarPubMed

Chen, WW, Blurton-Jones, M. Concise review: Can stem cells be used to treat or model Alzheimer’s disease? Stem Cells. 2012;30(12):2612–18.CrossRefGoogle ScholarPubMed

Sopova, K, Gatsiou, A, Stellos, K, Laske, C. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer’s Disease: From pathophysiology to novel treatment strategies. Curr Alzheimer Res 2014 Jan;11(1):27–39.CrossRefGoogle Scholar

Cummings, J, Zhong, K. Biomarker-driven therapeutic management of Alzheimer’s disease: Establishing the foundations. Clin Pharmacol Ther 2013 Oct 8. (Epub ahead of print.)CrossRefGoogle ScholarPubMed

Sigurdsson, EM. Tau immunotherapy and imaging. Neurodegener Dis 2014;13(2–3):103–6.CrossRefGoogle ScholarPubMed

Vellas, B, Aisen, PS, Sampaio, C, et al. Prevention trials in Alzheimer’s disease: an EU-US task force report. Prog Neurobiol 2011;95(4):594–600.CrossRefGoogle ScholarPubMed

Dubois, B, Feldman, HH, Jacova, C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9(11):1118–27.CrossRefGoogle Scholar

Jack, CR Jr, Albert, MS, Knopman, DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):257–62.CrossRefGoogle ScholarPubMed

Pollock, BG, Mulsant, BH, Rosen, J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007;15(11):942–52.CrossRefGoogle Scholar

Lanctôt, KL, Chau, SA, Herrmann, N, et al. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int Psychogeriatr 2014 Feb;26(2):239–46.CrossRefGoogle ScholarPubMed

Pioro, EP, Brooks, BR, Cummings, J, et al. Safety, tolerability, and efficacy results trial of AVP-923 in PBA investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010;68(5):693–702.CrossRefGoogle ScholarPubMed

Cummings, J, Isaacson, S, Mills, R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014 Feb 8;383(9916):533–40.Google Scholar